Pediatric HIV infection: The state of antiretroviral therapy

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 2, 2008, Pages 167-180

  McKellar, Mehri S ^a   Callens, Steven F J ^b   Colebunders, Robert ^c  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral therapy; HIV DNA RNA PCR; Non nucleoside reverse transcriptase inhibitor; Nucleoside analogue reverse transcriptase inhibitor; Pediatric HIV infection; Protease inhibitor

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; ANTIVIRAL ACTIVITY; APPLICATION SITE REACTION; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FOOD; FOOD DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCALCEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; LOW DRUG DOSE; MULTIDRUG RESISTANCE; NEUROTOXICITY; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; VIVID DREAM; DISEASE TRANSMISSION; INFANT; PRESCHOOL CHILD;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT;

EID: 45549098573     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.2.167     Document Type: Review

References (85)

1. de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284(2), 190-197 (2000).
2. Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N. Engl. J. Med. 345(21), 1522-1528 (2001).
3. Gona P, Van Dyke RB, Williams PL et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 296(3), 292-300 (2006).
4. US CDC. Cases of HIV Infection and AIDS in the United States, 2004. Department of Health and Human Services, GA, USA (2004).
5. US CDC. Achievements in public health. Reductiofi in perinatal transmission of HIV infection - United States, 190-2005. MMWR Morb. Mortal. Wkly Rep. 55(21), 592-597 (2006).
6. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29(5), 484-494 (2002).
7. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings. MMWR Recomm. Rep. 55(RR-14), 1-17; quiz CE11-CE14 (2006).
8. Newell ML, Coovadia H, Cortina-Borja M et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364(9441), 1236-1243 (2004).
9. Lujan-Zilbermann J, Rodriguez CA, Emmanuel PJ. Pediatric HIV infection: diagnostic laboratory methods. Fetal Pediatr. Pathol. 25(5), 249-260 (2006).
10. Children born to women with HIV-1 infection: natural history and risk of transmission. The European Collaborative Study. Lancet 337(8736), 253-260 (1991).
11. Rogers MF, Ou CY, Kilbourne B, Schochetman G. Advances and problems in the diagnosis of human immunodeficiency virus infection in infants. Pediatr. Infect. Dis. J. 10(7), 523-531 (1991).
12. Guay LA, Horn DL, Kabengera SR et al. HIV-1 ICD p24 antigen detection in ugandan infints: use in early diagnosis of infection and as a marker of disease progression. J. Med. Virol. 62(4), 426-434 (2000).
13. Fiscus SA, Wiener J, Abrams EJ et al. Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 45(7), 2274-2277 (2007).
14. George E, Beauharnais CA, Brignoli E et al. Potential of a simplified p24 assay for the early diagnosis of infant HIV-1 infection in Haiti. J. Clin. Microbiol. 45(10), 3416-3418 (2007).
15. Knuchel MC, Jullu B, Shah C et al. Adaptation of the ultrasensitive HIV-1 p24 antigen assay to dried blood spot testing. J. Acquir. Immune Defic. Syndr. 44(3), 247-253 (2007).
16. Dunn DT, Brandt CD, Krivine A et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 9(9), F7-F11 (1995).
17. Cunningham CK, Charbonneau TT, Song K et al. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr. Infect. Dis. J. 18(1), 30-35 (1999).
18. Patton JC, Akkers E, Coovadia AH et al. Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin. Vaccine Immunol. 14(2), 201-203 (2007).
19. Lambert JS, Harris DR, Stiehm ER et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of Perinatal HIV-1 infection. J. Acquir. Immune Defec. Syndr. 34(5), 512-519 (2003).
20. Shearer WT, Quinn TC, LaRussa P et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336(19), 1337-1342 (1997).
21. Steketee RW, Abrams EJ, Thea DM et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study. J. Infect. Dis. 175(3), 707-711 (1997).
22. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331(18), 1173-1180 (1994).
23. Saitoh A, Hsia K, Fenton T et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J. Infect. Dis. 185(10), 1409-1416 (2002).
24. Young NL, Shaffer N, Chaowanachan T et al. Early diagnosis of HIV- 1 -infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J. Acquir. Immune Defic. Syndr. 24(5), 401-407 (2000).
25. Obaro SK, Losikoff P, Harwell J, Pugatch D. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr. Infect. Dis. J. 124(2), 183-184 (2005).
26. Abrams EJ, Weedon J, Steketee RW et al. Association of human immunodeficiency virus (HM load early in fife with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J. Infect. Dis. 178(1), 101-108 (1998).
27. Ho DD. Viral counts count in HIV infection. Science 272(5265), 1124-1125 (1996).
28. Mofenson LM, Korelitz J, Meyer WA 3rd et al. The relationship between serum hurnan immunodeficiency vinis type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV- 1 -infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J. Infect. Dis. 175(5), 1029-1038 (1997).
29. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362(9396), 1605-1611 (2003).
30. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 22(1), 97-105 (2008).
31. Richardson BA, Nduati R, Mbori-Ngacha D, Overbaugh J, John-Stewart GC. Acute HIV infection among Kenyan infants. Clin. Infect. Dis. 46(2), 289-295 (2008).
32. Menson EN, Walker AS, Sharland M et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Br. Med. J. 332(7551), 1183-1187 (2006).
33. Verweel G, Burger DM, Sheehan NL et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir. Ther. 12(4), 453-458 (2007).
34. Buchacz K, Cervia JS, Lindsey JC et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 108(4), E72 (2001).
35. Shanbhag MC, Rutstein RM, Zaoutis T et al. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch. Pediatr. Adolesc. Med. 159(7), 651-656 (2005).
36. Storm DS, Boland MG, Gortmaker SL et al. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics 115(2), e173-e182 (2005).
37. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr. Infect. Dis. J. 22(7), 635-641 (2003).
38. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br. Med. J. 327(7422), 1019 (2003).
39. Vani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39(5), 725-731 (2004).
40. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. 121(5), 405-410 (2002).
41. Sanchez Torres AM, Munoz Muniz R, Madero R et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur. J. Pediatr. 164(5), 271-276 (2005).
42. Eshleman SH, Mracna M, Guay LA et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15(15), 1951-1957 (2001).
43. Johnson VA, Petropoulos CJ, Woods CR et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J. Infect. Dis. 183(11), 1688-1693 (2001).
44. Faye A, Bertone C, Teglas JP et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr. Infect. Dis. J. 21(6), 518-525 (2002).
45. Gray L, Newell ML, Thorne C, Peckham C, Levy J. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 108(1), 116-122 (2001).
46. Violari A, Cotton M, Gibb D et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study [WESS103]. Presented at: 4th MS Conftrence on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July 2007.
47. Abrams EJ, Wiener J, Carter R et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 17(6), 867-877 (2003).
48. Faye A, Le Chenadec J, Dollfus C et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin. Infect. Dis. 39(11), 1692-1698 (2004).
49. Luzuriaga K, McManus M, Mofenson L et al. A trial of three antiretroviral regimens in HIV-1-infected children. N. Engl. J. Med. 350(24), 2471-2480 (2004).
50. Luzuriaga K, McManus M, Catalina M et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J. Virol. 74(15), 6984-6991 (2000).
51. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
52. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 20(9), 1289-1294 (2006).
53. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 111(3), e275-e281 (2003).
54. McKinney RE Jr, Rodman J, Hu C et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infectied, therapy-naivc children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 120(2), e416-e423 (2007).
55. Scherpbier HJ, Bekker V, Pajkrt D et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 119(3), e705-e715 (2007).
56. Ananworanich J, Moor Z, Siangphoe U et al. Incidence and risk factors for rash in Thai patients randomized to regimens - with nevirapine, efavirenz or both drugs. AIDS 19(2), 185-192 (2005).
57. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
58. Sulkowski MS, Thomas DL, Mehra SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35(1), 182-189 (2002).
59. Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among ugandan children and adults treated with antirerroviral therapy. J. Acquir. Immune Defic. Syndr. 46(2), 187-193 (2007).
60. Funk MB, Notheis G, Schuster T et al. Effect of first fine therapy including efivirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur. J. Med Res. 10(12), 503-508 (2005).
61. Hitti J, Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PAC7G 1022. J. Acquir. Immune Defic. Syndr. 36(3), 772-776 (2004).
62. Verweel G, Sharland M, Lyall H et al. Nevirapine use in HIV-1-infected children. AIDS 17(11), 1639-1647 (2003).
63. Taylor P, Worrell C, Steinberg SM et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active andretroviral therapy regimens. Pediatrics 114(2), e235-e242 (2004).
64. Oldfield V, Plosker GL. Lopinavir/ritonavir. a review of its use in the management of HIV infection. Drugs 66(9), 1275-1299 (2006).
65. Saez-LlorensX, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediat, Infect. Dis. J. 22(3), 216-224 (2003).
66. DHHS. Pediatric Panel Notice on Nelfinavir FDA - Pfizer Letter. Mein R, Struble K (Eds). Washington, DC, USA (2007).
67. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lantivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36(5), 1011-1019 (2004)
68. Wang LH, Viznia AA, Rathore MH et al. Pharmacokinetics and safety of single oral doses of erntricitabine in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 48(1), 183-191 (2004).
69. Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidoivudine and zidovudine/abacavir beyond 5 years in children. AIDS 21(8), 947-955 (2007).
70. Bergshoeff A, Burger D, Verweij C et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir. Ther. 10(2), 239-246 (2005).
71. Stevens RC, Rodman JH, Yong FH et al. Effect offood and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res. Hum Retroviruses 16(5), 415-421 (2000).
72. Igoudjil A, Abbey-Toby A, Begriche K et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir. Ther. 12(3), 389-400 (2007).
73. Hernandez B, Moreno S, Perez-Elias MJ et al. Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients. J. Acquir. Immune Defic. Syndr. 43(5), 556-559 (2006).
74. Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fimnarate and an optimized background regimen of antiretroviral agents as salvage therapy. impact on bone mineral density in HIV-infected children. Pediatrics 118(3), e711-e718 (2006).
75. Perez-Elias MJ, Moreno A. Moreno S et al. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials 6(6), 312-319 (2005).
76. Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350(18), 1850-1861 (2004).
77. Srikantiah P, Walusimbi MN, Kayanja HK et al. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS 21(14), 1972-1974 (2007).
78. Wiznia A, Church J, Emmanuel P et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1 -infected patients. Pediatr. Infect. Dis. J. 26 (9), 799-805 (2007).
79. Meanwell NA, Kadow JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs 8(8), 669-681 (2007).
80. Raltegravir demonstrates potency. AIDS Patient Care STDS 21(4), 288 (2007).
81. TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor. AIDS Alert 22(2), 19-20 (2007).
82. Persaud D, Palumbo P, Ziemniak C et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J. Infect. Dis. 195(10), 1402-1410 (2007).
83. Flynn PM, Rudy BJ, Douglas SD et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1 -infected adolescents receiving highly active antiretroviral therapy. J. Infect. Dis. 190(2), 271-279 (2004).
84. Simoni J M, Montgomery A, Martin E et al. Adherence to antiretroviral therapy for A pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Petdiatrics 119(6), 6371-6383 (2007).
85. US CDC. 1994 Revised classification system for HIV infection in children less than 13 years of age. MMWR Morbid Mortal. Wkly Rep. 43, 1-10 (1994).